Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases
First-in-human study of PET and optical dual-modality image-guided surgery in glioblastoma using (68)Ga-IRDye800CW-BBN
First author：Li Deling,Zhang Jingjing,Chi Chongwei
Corresponding author：Tian Jie,Ji Nan,Zhu Zhaohui,Chen Xiaoyuan
essential_information
- Person in charge：Li Deling,Zhang Jingjing,Chi Chongwei
- Data Sources： OTHERS
- Number of papers：OTHERS20190611
- Published time：2018-04-03
2018-04-03
Published articles
Journal：Theranostics
Publication type: Research Paper
IF(IF): 11.556
PMID: 29721096 Link To Pubmed Full text Download
Background And Purpose
Method
We developed a novel 68Ga-IRDye800CW-BBN PET/near-infrared fluorescence (NIRF) dual-modality imaging probe targeting gastrin-releasing peptide receptor (GRPR) in GBM. The preclinical in vivo tumor imaging and FGS were first evaluated using an orthotopic U87MG glioma xenograft model. Subsequently, the first-in-human prospective cohort study (NCT 02910804) of GBM patients were conducted with preoperative PET assessment and intraoperative FGS.
Conclusion
This initial study has demonstrated that the novel dual-modality imaging technique is feasible for integrated pre- and intraoperative targeted imaging via the same molecular receptor and improved intraoperative GBM visualization and maximum safe resection.
Main results
The orthotopic tumors in mice could be precisely resected using the near-infrared intraoperative system. Translational cohort research in 14 GBM patients demonstrated an excellent correlation between preoperative positive PET uptake and intraoperative NIRF signal. The tumor fluorescence signals were significantly higher than those from adjacent brain tissue in vivo and ex vivo (p < 0.0001). Compared with pathology, the sensitivity and specificity of fluorescence using 42 loci of fluorescence-guided sampling were 93.9% (95% CI 79.8%-99.3%) and 100% (95% CI 66.4%-100%), respectively. The tracer was safe and the extent of resection was satisfactory without newly developed neurologic deficits. Progression-free survival (PFS) at 6 months was 80% and two newly diagnosed patients achieved long PFS.